As on Thursday, Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) started slowly as it slid -2.71% to $782.51, before settling in for the price of $804.33 at the close. Taking a more long-term approach, REGN posted a 52-week range of $784.96-$1211.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 19.99%. Meanwhile, its Annual Earning per share during the time was 10.31%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 2.31%. This publicly-traded company’s shares outstanding now amounts to $107.60 million, simultaneously with a float of $105.96 million. The organization now has a market capitalization sitting at $85.99 billion. At the time of writing, stock’s 50-day Moving Average stood at $992.70, while the 200-day Moving Average is $1,007.47.
Regeneron Pharmaceuticals, Inc (REGN) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Regeneron Pharmaceuticals, Inc’s current insider ownership accounts for 3.57%, in contrast to 86.42% institutional ownership. According to the most recent insider trade that took place on Nov 01 ’24, this organization’s EVP Commercial sold 1,000 shares at the rate of 844.61, making the entire transaction reach 844,610 in total value, affecting insider ownership by 12,931.
Regeneron Pharmaceuticals, Inc (REGN) Earnings and Revenue Records
Regeneron Pharmaceuticals, Inc’s EPS increase for this current 12-month fiscal period is 2.31% and is forecasted to reach 45.18 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 5.51% through the next 5 years, which can be compared against the 10.31% growth it accomplished over the previous five years trading on the market.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) Trading Performance Indicators
Let’s observe the current performance indicators for Regeneron Pharmaceuticals, Inc (REGN). It’s Quick Ratio in the last reported quarter now stands at 4.46. The Stock has managed to achieve an average true range (ATR) of 23.39. Alongside those numbers, its PE Ratio stands at $19.36, and its Beta score is 0.10. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 6.21. Similarly, its price to free cash flow for trailing twelve months is now 25.00.
In the same vein, REGN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 40.41, a figure that is expected to reach 11.11 in the next quarter, and analysts are predicting that it will be 45.18 at the market close of one year from today.
Technical Analysis of Regeneron Pharmaceuticals, Inc (REGN)
Through scrutinizing the latest numbers posted by the [Regeneron Pharmaceuticals, Inc, REGN], it can be observed that its last 5-days Average volume of 0.72 million was better the volume of 0.53 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 4.88% While, its Average True Range was 22.54.
Raw Stochastic average of Regeneron Pharmaceuticals, Inc (REGN) in the period of the previous 100 days is set at 0.36%, which indicates a major fall in contrast to 0.96% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 39.48% that was higher than 26.26% volatility it exhibited in the past 100-days period.
